DNA hypomethylation is the most common epigenetic change in cancer, but its origins often remain a mystery. Researchers recently investigated FAM83A in lung adenocarcinoma to determine if its activation signals an abnormality or a cellular redirection. They focused on how malignant cells shift their identity during tumor progression.

Single-cell RNA sequencing reveals that FAM83A is not present in whole lung tissue. However, it exists in specific airway epithelial cells like goblet and basal populations. In contrast, researchers found that the cancer-germline gene MAGEA1 remains silent across all normal lung cell types. This finding highlights a fundamental difference in how these genes behave during oncogenesis.

Clinical Implications of FAM83A in Lung Adenocarcinoma

The study demonstrated that FAM83A expression aligns with markers of airway lineages within malignant cells. Furthermore, malignant cells co-express FAM83A with NAPSA, which is a known marker of alveolar AT2 cells. Because lung adenocarcinoma originates from AT2 cells, this co-expression suggests a significant shift in cell program.

Consequently, the results indicate that FAM83A upregulation reflects a redirection of alveolar cells toward an airway differentiation program. Unlike MAGEA1, which stems from aberrant DNA demethylation, FAM83A activation follows an existing epithelial blueprint. This discovery provides a clearer understanding of how cancer cells hijack normal cellular programs to thrive.

Frequently Asked Questions

What makes FAM83A a unique biomarker in lung cancer?

FAM83A is unique because its expression in lung adenocarcinoma represents a redirection of alveolar cells toward an airway differentiation state, rather than just random genetic errors.

How does this research impact therapy?

Understanding that FAM83A follows an existing epithelial program may help doctors target the specific differentiation pathways that drive tumor progression and therapy resistance.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Professional medical guidance should always be sought for any health-related concerns. Refer to the latest local and national guidelines for clinical practice.

References

Wangermez C et al. Hypomethylation of FAM83A in lung adenocarcinoma mirrors an epigenetic signature of airway cell differentiation states. Discov Oncol. 2026 Jun 07. doi: 10.1007/s12672-026-05380-8. PMID: 42251611.

Singh P et al. Investigating the role of oncogenic FAM83A as a prognostic biomarker in lung adenocarcinoma: Insights from smoker and non-smoker cohorts. PMC. 2025.

PeerJ. High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma. 2023.